Business Description
![Vertex Pharmaceuticals Inc Vertex Pharmaceuticals Inc logo](https://static.gurufocus.com/logos/0C000009I3.png?14)
Vertex Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92532F1003
Share Class Description:
VRTX: Ordinary SharesCompare
Compare
Traded in other countries / regions
VRTX.USA0QZU.UKVX1.GermanyVRTX.MexicoVRTX34.BrazilVRTX.Austria1VRTX.Italy IPO Date
1991-07-31Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.21 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 2.01 | |||||
Interest Coverage | 100.43 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 15.32 | |||||
Beneish M-Score | -0.95 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 17.2 | |||||
3-Year EBITDA Growth Rate | 12.3 | |||||
3-Year EPS without NRI Growth Rate | 13.8 | |||||
3-Year FCF Growth Rate | 3.5 | |||||
3-Year Book Growth Rate | 26.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 9.74 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 52.67 | |||||
9-Day RSI | 51.22 | |||||
14-Day RSI | 50.63 | |||||
6-1 Month Momentum % | 14 | |||||
12-1 Month Momentum % | 39.85 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.52 | |||||
Quick Ratio | 2.26 | |||||
Cash Ratio | 1.63 | |||||
Days Inventory | 195.82 | |||||
Days Sales Outstanding | 57.25 | |||||
Days Payable | 92.9 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.3 | |||||
Shareholder Yield % | 0.89 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.45 | |||||
Operating Margin % | 40.61 | |||||
Net Margin % | -4.74 | |||||
FCF Margin % | -13.79 | |||||
ROE % | -2.96 | |||||
ROA % | -2.25 | |||||
ROIC % | -103.95 | |||||
ROC (Joel Greenblatt) % | 16.9 | |||||
ROCE % | 1.41 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 77.12 | |||||
PE Ratio without NRI | 2291.62 | |||||
Shiller PE Ratio | 91.6 | |||||
PEG Ratio | 55.35 | |||||
PS Ratio | 12.11 | |||||
PB Ratio | 8.4 | |||||
Price-to-Tangible-Book | 9.66 | |||||
EV-to-EBIT | 465.29 | |||||
EV-to-Forward-EBIT | 48.6 | |||||
EV-to-EBITDA | 256.61 | |||||
EV-to-Forward-EBITDA | 26.24 | |||||
EV-to-Revenue | 11.55 | |||||
EV-to-Forward-Revenue | 11.07 | |||||
EV-to-FCF | -83.71 | |||||
Price-to-Projected-FCF | 3.03 | |||||
Price-to-Median-PS-Value | 0.84 | |||||
Price-to-Peter-Lynch-Fair-Value | 133.68 | |||||
Price-to-Graham-Number | 31.37 | |||||
Price-to-Net-Current-Asset-Value | 34.65 | |||||
Price-to-Net-Cash | 283.08 | |||||
Earnings Yield (Greenblatt) % | 0.21 | |||||
FCF Yield % | -1.15 | |||||
Forward Rate of Return (Yacktman) % | 18.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vertex Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 10,337.4 | ||
EPS (TTM) ($) | -2.03 | ||
Beta | 0.45 | ||
Volatility % | 23.51 | ||
14-Day RSI | 50.63 | ||
14-Day ATR ($) | 9.411273 | ||
20-Day SMA ($) | 481.1885 | ||
12-1 Month Momentum % | 39.85 | ||
52-Week Range ($) | 340.83 - 510.635 | ||
Shares Outstanding (Mil) | 258.1 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Vertex Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Vertex Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Vertex Pharmaceuticals Inc Frequently Asked Questions
What is Vertex Pharmaceuticals Inc(VRTX)'s stock price today?
The current price of VRTX is $481.24. The 52 week high of VRTX is $510.64 and 52 week low is $340.83.
When is next earnings date of Vertex Pharmaceuticals Inc(VRTX)?
The next earnings date of Vertex Pharmaceuticals Inc(VRTX) is 2024-11-06 Est..
Does Vertex Pharmaceuticals Inc(VRTX) pay dividends? If so, how much?
Vertex Pharmaceuticals Inc(VRTX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |